Charles River Laboratories International, Inc. (CRL)
NYSE: CRL · Real-Time Price · USD
295.19
+3.74 (1.28%)
At close: Aug 21, 2026, 4:00 PM EDT
295.15
-0.04 (-0.01%)
After-hours: Aug 21, 2026, 7:38 PM EDT
CRL Stock Forecast
Stock Price Forecast
According to 16 analysts polled by S&P Global, CRL stock has a consensus rating of "Buy" and an average price target of $281. The average 1-year stock price forecast is 4.81% lower than the current stock price, while the lowest is $145 (-50.88%) and the highest is $318 (+7.73%).
Price Target: $281 (-4.81%)
Analyst Consensus: Buy
Price Target
ChartAnalyst Ratings
The average analyst rating for CRL stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Mar '26 | Apr '26 | May '26 | Jun '26 | Jul '26 | Aug '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 10 | 10 | 10 | 10 | 9 | 9 |
| Buy | 1 | 2 | 3 | 4 | 3 | 4 |
| Hold | 6 | 4 | 3 | 2 | 3 | 2 |
| Sell | 0 | 1 | 1 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 1 | 1 | 1 |
| Total | 17 | 17 | 17 | 17 | 16 | 16 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Mizuho Securities | Mizuho Securities | Hold Maintains $230 → $264 | Hold | Maintains | $230 → $264 | -10.57% | Aug 10, 2026 |
| TD Cowen | TD Cowen | Buy Reiterates $235 → $300 | Buy | Reiterates | $235 → $300 | +1.63% | Aug 10, 2026 |
| Morgan Stanley | Morgan Stanley | Buy Reiterates $260 → $300 | Buy | Reiterates | $260 → $300 | +1.63% | Aug 7, 2026 |
| Robert W. Baird | Robert W. Baird | Buy Maintains $255 → $291 | Buy | Maintains | $255 → $291 | -1.42% | Aug 6, 2026 |
| Deutsche Bank | Deutsche Bank | Buy Maintains $260 → $300 | Buy | Maintains | $260 → $300 | +1.63% | Aug 6, 2026 |
Financial Forecast
Revenue This Year
3.91B
from 4.02B
Decreased by -2.60%
Revenue Next Year
4.00B
from 3.91B
Increased by 2.29%
EPS This Year
11.32
from 10.28
Increased by 10.10%
EPS Next Year
12.69
from 11.32
Increased by 12.08%
EPS and Forward PE are based on non-GAAP adjusted numbers.